ATRA Polymer Conjugate Sustained Dermal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of all-trans retinoic acid (ATRA) for topical application suffer from rapid skin absorption, leading to adverse side effects such as skin irritation and hair loss, due to immediate bolus delivery, and microparticle approaches risk immunologic responses and infection.
Innovation Solution
A conjugated polymer is developed by covalently bonding ATRA to a hydrophilic polymer like polyvinyl alcohol (PVA) using a hydrolytically degradable ester linkage, creating a prodrug that forms an amphiphilic nanomaterial for sustained controlled delivery, enhancing dermal accumulation and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If ATRA is delivered as a single bolus through creams and emulsions, then the drug is immediately taken up into the skin, but this causes skin irritation and hair loss due to rapid increase in local concentration
Solution Approach 1:
The patent segments the bolus delivery into sustained release over time by incorporating ATRA into nanoparticles with controlled release kinetics. The drug is released gradually from the particle matrix rather than all at once, maintaining lower concentrations and avoiding the harmful effects of peak concentrations while still achieving therapeutic efficacy.
Solution Approach 2:
The patent introduces nanoparticles as an intermediary carrier between the ATRA drug and the skin. These particles control the release kinetics and mediate the delivery process, preventing direct bolus exposure that causes irritation while ensuring sustained therapeutic presence at the target site.
2Duration of action of moving object
If microparticle approaches are used for controlled release, then the delivery duration is extended, but injection across the dermis increases the potential for immunologic response and infection
Solution Approach 1:
The patent changes the size parameter of the delivery particles from microparticle scale to nanoparticle scale. This size reduction allows for non-invasive topical application rather than injection, eliminating the risk of immunologic response and infection associated with needle penetration while maintaining controlled release capabilities.
3Ease of manufacture
If ATRA is formulated in creams and emulsions, then the hydrophobic drug can be incorporated, but the formulation becomes immediately available for uptake, causing rapid concentration increase
Solution Approach 1:
The patent uses composite nanoparticle materials that combine hydrophobic and hydrophilic components. The hydrophobic core incorporates the ATRA drug, while the hydrophilic outer layer provides controlled release kinetics and compatibility with biological systems. This composite structure enables both easy drug incorporation and sustained release over extended periods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer-drug conjugate achieves sustained release of ATRA for up to 10 days in vitro and significantly reduces inflammation, maintaining drug presence at the application site for up to six days in vivo, while minimizing adverse reactions.
Implementation Method 1
an all-trans retinoid acid (ATRA) prodrug covalently bound to the polymer by a hydrolysable linker L
Implementation Method 2
significantly enhancing dermal accumulation of the ATRA in explant pig skin
Data Source
AI summary
Disclosed herein are conjugated polymers comprising a polymer and an all-trans retinoic acid (ATRA) prodrug covalently bound to the polymer by a hydrolysable linker L or a pharmaceutically acceptable salt thereof, and methods of using same to treat certain disorders. In an embodiment, the conjugated polymer comprises poly (vinyl alcohol) covalently bound to ATRA through an ester linkage.